Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended		3 Months Ended	9 Months Ended					0 Months Ended	1 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Segment	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014 Pharmaceutical Segment	Sep. 30, 2014 Diagnostics Segment	Sep. 30, 2014 Neovasc	Sep. 30, 2014 Neovasc	Sep. 30, 2014 Minimum	Sep. 30, 2014 Maximum	Sep. 30, 2014 Restatement Adjustment	Sep. 30, 2013 Restatement Adjustment	Aug. 30, 2013 Notes Due February 1, 2033 Notes	Jun. 30, 2014 Notes Due February 1, 2033 Notes	Sep. 30, 2014 Notes Due February 1, 2033 Notes	Jan. 31, 2013 Notes Due February 1, 2033 Notes	Sep. 30, 2013 Notes Due February 1, 2033 Notes Early conversion loss	Sep. 30, 2014 Notes Due February 1, 2033 Notes Early conversion loss Restatement Adjustment	Sep. 30, 2013 Notes Due February 1, 2033 Notes Early conversion loss Restatement Adjustment	Sep. 30, 2013 Notes Due February 1, 2033 Notes Change in derivative instruments	Sep. 30, 2014 Notes Due February 1, 2033 Notes Change in derivative instruments Restatement Adjustment
Summary of Significant Accounting Policies [Line Items]
Net cash used in operating activities			$ (65,618,000)	$ (29,603,000)								$ (6,400,000)	$ (2,500,000)
Net cash provided by financing activities			3,134,000	166,598,000								6,400,000	2,500,000
Gain on conversion of 3.00% convertible senior notes			(2,668,000)	(972,000)										(1,000,000)	(2,700,000)			8,700,000	(9,700,000)	(9,700,000)
Embedded Derivative, Loss on Embedded Derivative																					41,800,000	9,700,000
Convertible senior notes interest rate																3.00%	3.00%
Goodwill and intangible assets	1,100,000,000		1,100,000,000		1,100,000,000
Intangible assets, estimated useful lives										3 years	10 years
Amortization of intangible assets	2,735,000	2,790,000	8,304,000	8,192,000
Revenue from services	2,482,000	2,770,000	6,606,000	9,050,000				200,000	600,000
Revenue From Transfer Of Intellectual Property	0	1,308,000	476,000	16,080,000
Total deferred revenue related to other revenues	7,700,000		7,700,000		8,300,000
Allowance for doubtful accounts receivable	(1,432,000)		(1,432,000)		(1,885,000)
Equity-based compensation expense for continuing operations	$ 3,100,000	$ 400,000	$ 10,088,000	$ 7,411,000
Number of reportable segments			2
Number of operating segments						2	2